Royal Bank Of Canada set a $17.00 target price on Impax Laboratories, Inc. (NASDAQ:IPXL) in a report issued on Tuesday, October 17th. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.
IPXL has been the topic of a number of other research reports. Cantor Fitzgerald increased their price objective on Impax Laboratories from $20.00 to $25.00 and gave the stock an overweight rating in a report on Monday, September 11th. Zacks Investment Research raised Impax Laboratories from a hold rating to a buy rating and set a $23.00 price target on the stock in a report on Monday, October 16th. Deutsche Bank AG set a $21.00 price target on Impax Laboratories and gave the company a buy rating in a report on Monday, July 17th. Piper Jaffray Companies reaffirmed a hold rating and issued a $17.00 price target on shares of Impax Laboratories in a report on Sunday, September 17th. Finally, BMO Capital Markets reaffirmed a hold rating and issued a $16.00 price target on shares of Impax Laboratories in a report on Friday, June 23rd. Five analysts have rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the stock. Impax Laboratories has a consensus rating of Hold and a consensus price target of $19.14.
Shares of Impax Laboratories (NASDAQ:IPXL) traded down $0.38 during midday trading on Tuesday, hitting $18.18. The stock had a trading volume of 207,188 shares, compared to its average volume of 2,312,607. Impax Laboratories has a 1 year low of $7.75 and a 1 year high of $25.70. The company has a debt-to-equity ratio of 1.46, a current ratio of 1.75 and a quick ratio of 1.19. The stock has a market cap of $1,375.85, a PE ratio of 22.62, a PEG ratio of 1.06 and a beta of 0.99.
Impax Laboratories (NASDAQ:IPXL) last issued its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.04. The business had revenue of $202.08 million for the quarter, compared to analysts’ expectations of $195.62 million. Impax Laboratories had a positive return on equity of 9.05% and a negative net margin of 71.08%. The firm’s quarterly revenue was up 17.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.21 EPS. research analysts forecast that Impax Laboratories will post 0.7 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was published by BBNS and is owned by of BBNS. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://baseballnewssource.com/markets/impax-laboratories-inc-ipxl-pt-set-at-17-00-by-royal-bank-of-canada/1721280.html.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA lifted its stake in shares of Impax Laboratories by 67.0% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 39,233 shares of the specialty pharmaceutical company’s stock valued at $796,000 after purchasing an additional 15,735 shares during the period. Alps Advisors Inc. raised its stake in Impax Laboratories by 10.0% during the third quarter. Alps Advisors Inc. now owns 73,186 shares of the specialty pharmaceutical company’s stock valued at $1,486,000 after buying an additional 6,661 shares during the last quarter. Jennison Associates LLC purchased a new position in Impax Laboratories during the third quarter valued at $360,000. Stevens Capital Management LP purchased a new position in Impax Laboratories during the third quarter valued at $203,000. Finally, Frontier Capital Management Co. LLC raised its stake in Impax Laboratories by 2.2% during the third quarter. Frontier Capital Management Co. LLC now owns 1,620,548 shares of the specialty pharmaceutical company’s stock valued at $32,897,000 after buying an additional 34,720 shares during the last quarter. Institutional investors own 88.54% of the company’s stock.
Impax Laboratories Company Profile
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with our FREE daily email newsletter.